

K092229

Special 510(k): Device Modification  
Thyretain™ TSI Reporter BioAssay



**DATE OF PREPARATION OF 510(k) SUMMARY**

July 15, 2009

**APPLICANT**

DIAGNOSTIC HYBRIDS, INC.  
1055 East State Street  
Suite 100  
Athens, OHIO 45701

**MAY 18 2010**

**CONTACT INFORMATION**

Ronald H. Lollar  
Senior Director, Product Realization, Management, and Marketing  
E-mail: [lollar@dhiusa.com](mailto:lollar@dhiusa.com)  
Telephone: 740-589-3300  
Desk Extension: 740-589-3373  
FAX: 740-593-8437

**DEVICE NAME**

Trade name: Thyretain™ TSI Reporter BioAssay  
Common name: TSI Reporter  
Classification name: System, Test, Thyroid Autoantibody  
Product Code: JZO  
Regulation: 21 CFR § 866.5870, Thyroid Autoantibody Immunological Test

**LEGALLY MARKETED DEVICE**

Thyretain™ TSI Reporter BioAssay (TSI Reporter), K083391

**DESCRIPTION of DEVICE MODIFICATION**

The number of wells tested per Positive, Reference and Negative control has been reduced from three to two for each. The number of wells tested per patient specimen has been reduced from three to two.

**INTENDED USE**

The Thyretain™ TSI Reporter BioAssay is intended for the qualitative detection in serum of thyroid stimulating autoantibodies to the thyroid stimulating hormone (TSH) receptors (TSHRs) on the thyroid. The detection of these stimulating autoantibodies, in conjunction with other clinical and laboratory findings, may be useful as an aid in the differential diagnosis of patients with Graves' disease (GD).

**ASSESSMENT OF NON-CLINICAL PERFORMANCE DATA FOR EQUIVALENCE**

Not Applicable

**ASSESSMENT OF NON-CLINICAL PERFORMANCE DATA FOR EQUIVALENCE**

The risk analysis method used to assess the impact of the modification was a Failure Modes and Effects Analysis (FMEA). Based on the analysis of the study site data (see Attachment 2) the modification poses little risk.

**BIOCOMPATABILITY**

Not applicable

**STERILIZATION**

Not applicable



## DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Mail Center – WO66-0609  
Silver Spring, MD 20993-0002

Diagnostic Hybrids, Inc  
c/o Mr. Ronald H. Lollar  
Senior Director, Product Realization, Management and Marketing  
1055 East State Street, Suite 100  
Athens, Ohio 45701

**MAY 18 2010**

Re: k092229

Trade/Device Name: Thyretain™ TSI Reporter BioAssay  
Regulation Number: 21 CFR §866.5870  
Regulation Name: Thyroid autoantibody immunological test system  
Regulatory Class: Class II  
Product Code: JZO  
Dated: May 14, 2010  
Received: May 17, 2010

Dear Mr. Lollar:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice


Page 2 – Mr. Ronald H. Lollar

requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Maria M. Chan, Ph.D  
Director  
Division of Immunology and Hematology Devices  
Office of *In Vitro* Diagnostic Device Evaluation and Safety  
Center for Devices and Radiological Health

Enclosure

## Indication for Use

510(k) Number (if known): k092229

Device Name: Thyretain™ TSI Reporter BioAssay

### Indication For Use:

The Thyretain™ TSI Reporter BioAssay is intended for the qualitative detection in serum of thyroid stimulating autoantibodies to the thyroid stimulating hormone (TSH) receptors (TSHRs) on the thyroid. The detection of these stimulating autoantibodies, in conjunction with other clinical and laboratory findings, may be useful as an aid in the differential diagnosis of patients with Graves' disease (GD).

Prescription Use  (21 CFR Part 801 Subpart D)

And/Or

Over the Counter Use  (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

Reena Philip  
Division Sign-Off  
Office of In Vitro Diagnostic Device  
Evaluation and Safety

510(k) k092229